Search / 289 results found


TUESDAY, Jan. 25, 2022 (HealthDay News) -- A four-marker protein panel (4MP), including the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fragment, combined with the prostate lung colorectal ovarian cancer risk prediction model (PLCOm2012) may improve risk assessment and help identify candidates for lung cancer screening, according to a study published online Jan. 7 in the Journal of Clinical Oncology.